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Introduction. A subgroup of septic shock patients will never develop hyperlactatemia despite being subjected to a massive
circulatory stress. Maintenance of normal lactate levels during septic shock is of great clinical and physiological interest. Our aim
was to describe the clinical, hemodynamic, perfusion, and microcirculatory profiles associated to the absence of hyperlactatemia
during septic shock resuscitation. Methods. We conducted an observational study in septic shock patients undergoing resuscitation.
Serial clinical, hemodynamic, and perfusion parameters were registered. A single sublingual microcirculatory assessment was
performed in a subgroup. Patients evolving with versus without hyperlactatemia were compared. Results. 124 septic shock
patients were included. Patients without hyperlactatemia exhibited lower severity scores and mortality. They also presented
higher platelet counts and required less intensive treatment. Microcirculation was assessed in 45 patients. Patients without
hyperlactatemia presented higher PPV and MFI values. Lactate was correlated to several microcirculatory parameters. No
difference in systemic flow parameters was observed. Conclusion. Persistent sepsis-induced hypotension without hyperlactatemia is
associated with less organ dysfunctions and a very low mortality risk. Patients without hyperlactatemia exhibit less coagulation and
microcirculatory derangements despite comparable macrohemodynamics. Our study supports the notion that persistent sepsis-
induced hypotension without hyperlactatemia exhibits a distinctive clinical and physiological profile.
1. Introduction
Although the physiologic basis of lactate generation during
shock has been recently matter of debate and research, a
perfusion-related mechanism is probably involved at least
in early stages [1–3]. Recent clinical studies have confirmed
the strong prognostic value of hyperlactatemia and its asso-
ciation to other hemodynamic and perfusion abnormalities
in septic shock [4–6]. Either a single abnormal level or
an impaired lactate clearance is related to morbidity and
mortality.
More intriguingly, a subgroup of septic patients requir-
ing prolonged vasopressor support, and thus classified
as septic shock according to the 2001 Sepsis Definition
Conference [7], will never develop hyperlactatemia despite
being subjected to a massive circulatory stress [8, 9].
Moreover, we recently performed a retrospective analysis of
302 vasopressor-requiring septic patients, and demonstrated
that the absence of hyperlactatemia was associated with a
very low (7.7%) mortality risk as compared with that in
patients presenting hyperlactatemia at some point during
resuscitation (42%) [9].
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The maintenance of normal lactate levels in a septic
patient with circulatory dysfunction is of great clinical
and physiological interest. In fact, since several potential
mechanisms can induce hyperlactatemia, including low
cardiac output, microcirculatory abnormalities, sustained
hyperadrenergia with accelerated aerobic glycolysis, and
hepatosplanchnic hypoperfusion, among others, it is likely
that the absence of hyperlactatemia reflects a more adequate
physiological response to stress [1, 9]. Indeed, the very low
mortality associated to this condition supports the notion
of a relatively preserved global homeostasis [9]. However,
this statement is highly speculative and should be addressed
in additional clinical and physiological research specifically
focused on the determinants of lactate homeostasis during
sepsis-related circulatory dysfunction.
Our aim was to describe the clinical, hemodynamic,
perfusion, and microcirculatory profiles associated to the
absence of hyperlactatemia during septic shock resuscitation
as a hypothesis-generating study.
2. Patients and Methods
We conducted an observational study from April 2008
to October 2010, including all adult patients admitted
to the ICU with a diagnosis of septic shock according
to the 2001 Sepsis Definition Conference [7]. Under this
definition, septic patients are considered in shock when
presenting a volume-refractory hypotension and thus require
vasopressors to sustain blood pressure.
All septic shock patients were treated with a periodically
updated management protocol independently of their partic-
ipation in this study, and their demographic and clinical data
were registered in a prospective data set. The Institutional
Review Board (IRB) of our University approved this study
and waived the necessity of an informed consent because
of the solely observational nature of the study design, and
considering that it did not deviate from the best standard of
care.
Patients requiring vasopressors to maintain mean arterial
pressure (MAP) > 65 mmHg despite initial fluid loading [10]
and committed to full resuscitation were considered eligible
for this study.
Our local management algorithm for septic shock has
been published elsewhere [9, 11–14]. Septic patients present-
ing a circulatory dysfunction at the emergency department
(ED) or the pre-ICU service were subjected to vigorous fluid
resuscitation and basal measurements of lactate (Radiometer
ABL 735, Copenhagen Denmark). If developing persistent
hypotension or hyperlactatemia, patients were transferred to
the ICU as soon as a bed was available. In the meantime, and
depending on the timing of ICU bed availability, a central
venous catheter was inserted for measurement of central
venous oxygen saturation. The mean transfer time from the
ED to the ICU for septic shock patients in our university
hospital is 48 minutes [14].
ICU-based resuscitation was aimed at normalizing
macrohemodynamic and clinical and metabolic perfu-
sion parameters. Invasive hemodynamic monitoring and
mechanical ventilation (MV) were decided on an individual
basis by attending physicians. Norepinephrine (NE) was used
as the sole vasopressor and adjusted to the minimal dose to
maintain the MAP target. Optimal fluid resuscitation was
guided by dynamic predictors [15] or by a Starling curve
approach when the former were not feasible. High-volume
hemofiltration (HVHF) was indicated as a final salvage
therapy in unresponsive patients [13]. Intra-abdominal
pressure was monitored and treated according to recent
guidelines [16]. Complementarily, a dedicated sepsis team
performed a daily exhaustive reassessment of the adequacy
of source control and participated in major decisions.
Perfusion assessment included metabolic (arterial lactate,
central (ScvO2) or mixed (SvO2) venous O2 saturation,
central venous-to-arterial PCO2 difference (P(cv-a)CO2))
and peripheral perfusion parameters (capillary refill time,
central-to-peripheral temperature gradient, skin mottling) at
least every 6 h during the first 48 h of treatment. A patient
with septic shock was subjected to at least 9 arterial lactate
determinations (including the first pre-ICU assessment)
during this period.
A patient was considered as resuscitated when normaliza-
tion of both metabolic and peripheral perfusion parameters
was achieved, while maintaining stable or decreasing NE
requirements for at least 12 h. Patients were followed until
hospital discharge or death. Baseline values were registered
after arterial line and central venous catheter insertion.
Sublingual microcirculatory assessments were performed
within 6 h of ICU resuscitation in a subgroup of patients (see
below).
We divided the whole cohort according to the presence
or not of any abnormal lactate value during the resuscitation
period and compared the resulting subgroups for differences
in mortality and other relevant clinical and physiological
variables. To be classified to the “normal” lactate subgroup,
all lactate measurements including the pre-ICU determina-
tions had to be in the normal range. Patients with at least
one abnormal level were classified to the “hyperlactatemia”
subgroup.
3. Lactate Determination
Lactate levels were measured in arterial blood using the
hospital’s central laboratory through a blood gas analyzer
(Radiometer ABL 735, Copenhagen, Denmark). According
to our laboratory standards, a range from 0.1 to 2.4 mmol/L
was considered as normal. This cut-off was recently revali-
dated by Shapiro et al. [4].
3.1. Sublingual Microcirculation Imaging. Microcirculatory
assessments were performed in all septic shock patients
included after April 2010. At this point, proper training
of staff in image acquisition was completed, thus allowing
around-the-clock availability. A different investigator, who
was blinded to clinical data, performed image analysis
according to a recent consensus [17].
Sublingual microcirculation was assessed with sidestream
dark field (SDF) videomicroscopy with a 5x lens (Microscan
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for NTSC, Microvision Medical). At each time point, at least
five 10–20 sec images were recorded. After removing saliva
and oral secretions, the probe was applied over the mucosa
at the base of the tongue. Special care was taken to avoid
exerting excessive pressure on the mucosa, which was verified
by checking ongoing flow in larger microvessels (>50 um).
Analog images were digitalized by using the pass-through
function of a digital video camera recorder (Sony DCR-
HC96, for NTSC) and were recorded instantaneously and
transformed to AVI format in a laptop with the aid of a
commercial software (DVGate Plus 2.3, Sony Corporation).
According to recommendations of the cited consensus
[17], image analysis consisted in flow (percentage of perfused
vessels, PPV; microcirculatory blood flow, MFI), density
(total vascular density, TVD; perfused vascular density, PVD)
and heterogeneity parameters (MFI heterogeneity, Het MFI).
Briefly, to determine MFI, the image was divided into four
quadrants and the predominant type of flow is assessed in
each quadrant and characterized as absent = 0, intermittent =
1, sluggish = 2, or normal = 3. Values of the 4 quadrants
were averaged. MFI heterogeneity was calculated as Het
MFI = (MFI max − MFI min) × 100/MFI mean. For
TVD and PVD, a gridline consisting of 3 horizontal and 3
vertical equidistant lines was superimposed on the image. All
vessels crossing the lines were counted and classified either
as perfused (continuous flow) or nonperfused (no flow or
intermittent flow) vessels. Next, densities were calculated as
the total number of vessels (TVD) or the number of perfused
vessels (PVD), divided by the total length of the gridline in
millimeters. PPV was calculated as PVD/TVD × 100 [17].
4. Statistical Analysis
In order to accomplish our objectives, patients evolving with
versus without hyperlactatemia were compared for differ-
ences in severity scores, organ dysfunctions, hemodynamic
and perfusion parameters, microcirculatory abnormalities,
and hospital mortality.
Numerical variables were compared using Mann-
Whitney U test, and categorical variables were compared
by chi-square goodness-of-fit test. Spearman’s correlation
was used for testing between continuous variables, due to
nonnormal distribution of data. Logistic and multivariate
regression was performed to determine variables indepen-
dently associated with hyperlactatemia, microcirculatory
abnormalities, and hospital mortality. SPSS software version
17.0 (Chicago, IL, USA) was used for statistical calcula-
tions. Results are expressed as percentages or median and
interquartile range. A P < 0.05 was considered as statistically
significant. All reported P values are two sided.
5. Results
A total of 124 patients were included in this study. The
general characteristics of the cohort are shown in Table 1.
Thirty-eight patients (31%) did not present hyperlactatemia
during resuscitation and 86 (69%) did. Sepsis was caused
more frequently by abdominal and respiratory sources.
Surgical resolution of sepsis foci was necessary in 39%.
When comparing both subgroups, no difference in co-
morbidities was found (Table 1). Patients without hyperlac-
tatemia presented lower severity scores, less MV require-
ments, and lower hospital mortality (Table 1). They also
exhibited higher platelet counts and lower serum creatinine
levels (Table 2).
In relation to hemodynamic and perfusion parameters,
patients with persistent sepsis-induced hypotension without
hyperlactatemia presented lower NE requirements, less pos-
itive fluid balances, and received dobutamine less frequently
(Table 3). A pulmonary artery catheter was inserted in 9
patients without hyperlactatemia and in 38 with elevated
lactate levels. No significant differences in cardiac index,
pulmonary artery occlusion pressure, ScvO2, and SvO2 were
observed.
A sublingual microcirculatory assessment was performed
in 45 patients (36% of the whole cohort; see above), 14
without and 31 with hyperlactemia. This subset was com-
parable to the whole cohort in clinical, hemodynamic, and
perfusion variables, and outcome. When comparing sub-
groups, patients without hyperlactatemia exhibited signifi-
cantly higher PPV and MFI values (Table 4).
In the subset of patients in whom a sublingual microcir-
culatory assessment was performed, lactate levels exhibited
a significant correlation with PPV (Spearman’s Rho = 0.499,
P < 0.0001) and MFI (Spearman’s Rho = 0.497, P < 0.0001).
6. Discussion
Our results confirm that patients with persistent sepsis-
induced hypotension without hyperlactatemia present a very
low mortality risk. This condition is associated with less
organ dysfunctions and intensity of ICU management. Age,
comorbidities, sepsis source control, and macrohemody-
namic parameters including cardiac output, were not related
to the presence or absence of hyperlactatemia. Interest-
ingly, patients without hyperlactatemia presented less severe
microcirculatory abnormalities and higher platelet counts.
Although our conclusions are to some extent speculative
and basically hypothesis generating, these data support the
notion that patients with persistent sepsis-induced hypoten-
sion without hyperlactatemia exhibit a distinctive clinical
and physiological profile.
Sepsis involves a complex interaction between the
coagulation and inflammatory systems at the endothelial
and microvascular level [18, 19]. This may result in tis-
sue hypoperfusion, thus inducing hypoxia-driven hyperlac-
tatemia [20]. Moreover, disseminated intravascular platelet
activation may occur, contributing to microvascular failure
and organ dysfunction [21]. Thrombocytopenia is a marker
of this process. On the other hand, several microcircula-
tory abnormalities, such as endothelial edema, leukocyte
activation, red blood cells stiffness, platelet aggregation,
and functional shunting, could also induce microvascular
hypoperfusion and eventually hyperlactatemia [22].
In effect, patients without hyperlactatemia evolved with
higher platelet counts, a trend to lower D-dimer levels
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Table 1: General characteristics of the cohort and subgroups of patients.
Total Lactate < 2.5 Lactate ≥ 2.5
Number of patients 124 38 86
Age (y) 65 [53–75] 62 [39–73] 65 [58–75]
ICU LOS (d) 5 [3–9] 4.5 [2–7] 5 [3–10]
APACHE II score 18 [12–24] 12 [8–19] 20 [15–25]∗∗
Basal SOFA score 8 [5–10] 6 [3–8] 9 [6–11]∗∗
ICU mortality (%) 13.7 5.2 17.4∗
Hospital mortality (%) 17.6 7.9 20.9∗
Patients in MV (%) 79 71 82∗
Length of MV (d) 2 [1–5] 1 [0–3.7] 3 [1–7]∗
Renal replacement therapy 19 3 16∗
Sepsis source (%)
Pulmonary 27 26 28
Abdominal 45 45 44
Other 28 29 28
Adequate initial AB empiric coverage (%)
Yes 81 71 85
No 13 16 12
Unknown 6 13 3
Comorbidities (%)
Diabetes 20 19 21
Hypertension 26 23 27
Chronic kidney disease 7 6 8
Stroke 24 0 3
Atrial fibrillation 11 0 15
∗
P < 0.05 for the comparison between subgroups.
∗∗P < 0.01 for the comparison between subgroups.
Data are shown as median [interquartile range] or percentage. ICU: intensive care unit; LOS: length of stay; APACHE: acute physiology and chronic health
evaluation; SOFA: sequential organ failure assessment; MV: mechanical ventilation; AB: antibiotic.
Table 2: Baseline and peak laboratory parameters of organ dysfunction.
Lactate < 2.5 mmol/l Lactate ≥ 2.5 mmol/l
Baseline PaO2/FiO2 260 [185–388] 275 [160–339]
Lowest PaO2/FiO2 257 [184–340] 218 [150–286]
Baseline D-dimer levels (ng/mL) 3070 [2031–4198] 3788 [2096–5480]
Peak D-dimer levels (ng/mL) 3447 [2182–4771] 5298 [2885–7392]
Baseline platelet count (×103/mm3) 192 [157–332] 145 [101–255]∗
Lowest platelet count (×103/mm3) 171 [116–261] 83.5 [43.3–162.5]∗∗
Baseline bilirubin levels (mg/dL) 0.7 [0.5–1.3] 1 [0.6–1.9]
Peak bilirubin levels (mg/dl) 0.7 [0.6–1.7] 1.1 [0.7–3]
Baseline C-reactive protein levels (mg/dL) 15.9 [8.5–25.9] 14.7 [5.7–27.6]
Peak C-reactive protein levels (mg/dL) 24.4 [15.2–33.9] 28 [19.7–36]
Baseline serum creatinine levels (mg/dL) 0.8 [0.6–1.6] 1.7 [1–3]∗∗




Data are shown as median [interquartile range].
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Table 3: Hemodynamic and perfusion parameters in subgroups of patients.
Lactate < 2.5 mmol/L Lactate ≥ 2.5 mmol/L
Peak lactate level (mmol/l) 1.7 [1.3–2] 4.5 [3.4–7.4]∗∗
Baseline lactate levels (mmol/l) 1.2 [1–1.8] 4 [3–5.8]∗∗
Baseline PAOP (mmHg) 18 [13–26.5] 19.5 [15.3–23.8]
Baseline CI (l/min/m2) 3.2 [1.9–3.5] 3 [2.4 –3.7]
Lowest CI (l/min/m2) 2 [1.9–3.2] 2.4 [2 –2.7]
Lowest ScvO2 (%) 67 [59–71] 66 [58 –72]
Lowest SvO2 (%) 69 [65 –74] 68 [61 –75]
Peak NE dose (ug/kg/min) 0.08 [0.04 – 0.17] 0.2 [0.07–0.53]∗∗
NE use (h) 22 [11–41] 35 [17–69]∗
24 h fluid balance (mL) 1903 [845–2835] 4000 [1973–5509]∗∗
Cumulative 72 h fluid balance (mL) 2857 [1130–5264] 5978 [3674–9551]∗∗
Dobutamine use (% of patients) 18 46∗∗
Basal P(cv-a)CO2(mmHg) 5.5 [3–8] 6.1 [4.7–8]




Data are shown as median [interquartile range] or percentage. PAOP: pulmonary artery occlusion pressure; CI: cardiac index; ScvO2: central venous oxygen
saturation; SvO2: mixed venous oxygen saturation; NE: norepinephrine; P(cv-a)CO2: central venous-to-arterial PCO2 difference.
Table 4: Hemodynamic, perfusion and microcirculatory parameters in 45 patients evaluated with sublingual SDF videomicroscopy.
Lactate < 2.5 mmol/L Lactate ≥ 2.5 mmol/L
n (%) 14 (31%) 31 (69%)
NE (ug/kg/min) 0.2 [0.09–0.39] 0.48 [0.22–0.93]∗
Lactate (mmol/l) 1.4 [1.2–2.1] 5.8 [3.9–8.4]∗
ScvO2 (%) 73 [67–77] 71 [66–78]
TVD (n/mm) 12.9 [10.7–13.9] 12.9 [11.1–14.9]
PVD (n/mm) 10.5 [9.5–12] 10.1 [6.6–12.4]
PPV (%) 87.3 [81.6–90.6] 75.5 [60.9–86.4]∗
MFI 2.44 [2.25–2.61] 2.11 [1.7–2.32]∗
Het MFI 0.33 [0.18–0.49] 0.42 [0.27–0.72]
∗
P < 0.01
Data are shown as median [interquartile range] or percentage. NS: nonsignificant (P > 0.05). NE: norepinephrine; ScvO2: central venous oxygen saturation;
P(cv-a)CO2: central venous-to-arterial PCO2 difference; TVD: total vascular density; PVD: perfused vascular density; PPV: percentage of perfused vessels;
MFI: microvascular flow index; Het MFI: MFI heterogeneity.
(P = 0.08), and a relatively preserved microcirculatory
flow (PPV and MFI). Taken together, these data suggest
that the absence of hyperlactatemia could be related, at
least in part, to less severe endothelial and microcirculatory
dysfunctions. As a matter of fact, macrohemodynamic
variables, oxygen-derived parameters such as SvO2, and
venous-arterial pCO2 gradients were not different between
subgroups, thus suggesting that systemic flow disturbances
are not major determinants of the genesis of hyperlactatemia
in this setting.
The relationship between hyperlactatemia and micro-
circulatory abnormalities in septic patients is somehow
controversial. Three studies reported a poor correlation
between MFI and hyperlactatemia after single assessments
[23–25]. In contrast, De Backer et al., testing the effect of
dobutamine on microcirculatory abnormalities, found that
an improvement in PPV was significantly associated with a
decrease in lactate levels [26]. The same group confirmed
these findings in another study addressing the effects of
fluids on microvascular flow [27]. These discrepancies could
be better explained by different study designs, concerning
timing and number of microcirculatory assessments and
therapeutic interventions. As a matter of fact, the latter
group [26, 27] performed 2 sequential microcirculatory eval-
uations, thus comparing the time course of microvascular
flow recovery and lactate decrease. In our case, although we
performed a single microcirculatory assessment per patient,
the main difference with the studies cited above [23–25] is
that we compared microcirculatory derangements between
two mutually exclusive subgroups and found a significant
correlation between several microcirculatory flow-related
parameters and lactate. Although methodological differences
preclude a direct comparison between studies, in our opinion
they ultimately suggest that there is an effective association
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between hyperlactatemia and microcirculatory abnormali-
ties, at least during the early stages of septic shock. However,
no definite cause-effect relationship can be established at this
point.
Another interesting finding is the relatively moderate
degree of microcirculatory derangements found in our study,
as shown by a mean MFI of 2.1 and a PPV of 75.5% in
patients with hyperlactatemia. However, while our obser-
vation is consistent with recent studies that found similar
mean basal MFI values [28–30], it is in sharp contrast with
another trial reporting MFI values of less than 1.5 early
after emergency room admission [31]. Moreover, Boerma
et al. [32] reported that MFI improved over time (from
1.4 to 2.2) during resuscitation in the placebo arm of their
nitroglycerin trial. These data considered together suggest
that MFI values are very low in nonresuscitated patients
but may improve rapidly after initial aggressive resuscitative
maneuvers, resembling what happens with ScvO2. Never-
theless, this fact does not invalidate our results, since both
subgroups, with and without hyperlactatemia, presented
similar pre-ICU management and time from diagnosis to
ICU admission (data not shown). Therefore, we believe that
the observed differences in microcirculatory flow indexes
are relevant and provide interesting potential clinical and
physiological implications.
Our study suggests that persistent sepsis-induced
hypotension without hyperlactatemia, traditionally included
under septic shock definitions, constitutes a different
subgroup in terms of prognosis and endothelial/micro-
circulatory dysfunction. Remarkably, more than 90%
of these patients had this condition resolved and were
discharged from ICU without further complications.
Moreover, they required less intensive critical care treatment.
The 2001 Sepsis Definition Conference proposed vasopressor
requirements as a mandatory criterion for septic shock
diagnosis, irrespective of lactate levels [7]. In this sense,
besides confirming our previous retrospective findings [9],
the present study provides more clinical and physiological
data for a potential reappraisal of current septic shock
definitions. The question whether persistent sepsis-induced
hypotension without hyperlactemia constitutes a different
pathophysiological entity, or simply a mild form of septic
shock, should be addressed in future studies.
Our study has several limitations. This was a single-
centre study, thus limiting the extrapolation of our results.
Microcirculatory assessments were performed at different
time points during early resuscitation, were limited to a
subset of patients, and did not include serial measurements.
We did not evaluate other potential mechanisms involved in
the genesis of hyperlactatemia, such as hyperadrenergia with
accelerated glycolysis, hepatosplanchnic flow, or mitochon-
drial dysfunction. No sample size calculation was performed,
and our cohort was relatively small. We cannot rule out
the possibility of having missed some high lactate values
between sampling, although this is unlikely considering the
frequent sampling. Finally, it was beyond our scope to
comprehensively address all the potential causes of persistent
hyperlactatemia. As stated in the introduction, this has
been matter of extensive recent research, but briefly many
potential nonhypoxic causes could contribute including hep-
atosplanchnic hypoperfusion, liver dysfunction, adrenergic-
driven aerobic glycolysis, hyperinflammation, among others
[1–3]. Nevertheless, we think that these results provide valu-
able information concerning the clinical and physiological
significance of the absence of hyperlactatemia during sepsis-
related circulatory dysfunction.
7. Conclusions
Persistent sepsis-induced hypotension without hyperlac-
tatemia is associated with less severe organ dysfunctions
and a very low mortality risk. Systemic flow parameters are
not related to the presence or absence of hyperlactatemia.
Our data suggest a relationship between coagulation, micro-
circulatory derangements, and lactate levels. This study
tends to support the notion that patients with persistent
sepsis-induced hypotension without hyperlactatemia exhibit
a distinctive clinical and physiological profile within the
spectrum of septic shock. This subject should be addressed
in future studies.
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